Jacobs Journal of Internal Medicine

Prostate Specific Antigen (PSA) Derivatives for Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia Subjects in Sokoto, Nigeria

*Nnamah NK
Department Of Chemical Pathology, Nnamdi Azikwe University, Nnewi, Nigeria

*Corresponding Author:
Nnamah NK
Department Of Chemical Pathology, Nnamdi Azikwe University, Nnewi, Nigeria

Published on: 2018-08-01


Over the years, many markers have been used for the diagnosis and follow-up of prostate disorders. With its attendant limitations, PSA is the most common marker used. In the present study, PSA ratios; fPSA/cPSA, fPSA/tPSA and cPSA/tPSA were evaluated in 150 prostate cancer (PCa), 200 benign hyperplasia (BPH) patients and 200 controls. Using Mann-Whitney U-Test, free PSA/complexPSA ratio (fPSA/cPSA) was 0. 18±0.01, 0.34±0.02, 0.48±0.02, freePSA/totalPSA ratio (fPSA/tPSA) was 0.19±0.11, 0.34±0.23 and 0.48±0.23 while complexPSA/totalPSA ratio (cPSA/tPSA) was 0.85±0.01, 0.7±0.01 and 0.70±0.01 in PCa, BPH and controls respectively. The difference in the ratios between all the groups are significant (p<0.01). Evidence from the current study suggested that, diagnosis and prognosis of prostate disorders can be widened and more steps need to be taken to determine the efficacy of these markers.


PSA: Prostate Specific Antigen (PSA) ratios; PCa: Prostate cancer (PCa); BPH: Benign prostatic hyperplasia (BPH); diagnostic value


The outstanding successes achieved in the treatment of prostate cancer should be credited to the “golden five” of this era, namely imaging, radiation, chemotherapy, surgery and screening programs [1]. For the past few years, serum PSA estimation has raised quite a cloud when it comes to its effectiveness as a biological marker for the detection of prostate disorders. Its deficiencies have given rise to serious efforts are made to improve its specificity by combining it with other existing biomarkers or discover and define new ones as an adjunct [2]. Serum PSA measurements show variable reliability when it comes to diagnosis of prostate disorders hence stimulating efforts to detect many more markers to aid early detection and treatment.